Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Competing interests T.K.C. reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy and/or honoraria past 10 years, ongoing or not, from Alkermes, Arcus Biosciences, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Bicycle Therapeutics, Calithera, Caris, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, HiberCell, IQVA, Infinity, Institut Servier, Ipsen, Janssen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME and non-CME events (Mashup Media Peerview, OncLive, MJH, CCO and others) and Xencor (outside the submitted work); reports institutional patents filed on molecular alterations and immunotherapy response/toxicity, rare genitourinary cancers and ctDNA/liquids biopsies; reports equity in Abalytics, CureResponse, Faron Pharma, InnDura Therapeutics, Osel, Pionyr, Precede Bio, Primium and Tempest; reports serving on committees for ACCRU, ASCO (BOD 6/2024-), ESMO, GU steering committee, KidneyCan and NCCN; reports medical writing and editorial assistance support that may have been funded by communications companies in part; reports mentorship of several non-US citizens on research projects with potential funding (in part) from non-US sources/foreign components; reports that the institution (Dana-Farber Cancer Institute) may have received additional …